Etodolac

• UNSPSC Description:

  Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)

• Target Antigen:

  COX

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/etodolac.html

• Purity:

  99.77

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CC(OCC1)(CC)C2=C1C3=CC=CC(CC)=C3N2

• Molecular Weight:

  287.35

• References & Citations:

  [1]Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.|[2]Ito S, Tajima K, Nogawa M et al. Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. J Pharmacol Exp Ther. 2012 Jul;342(1):53-60.|[3]Yanaoka K, Oka M, Yoshimura N et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer. 2010 Mar 15;126(6):1467-73.|[4]Matsuyama M, Yoshimura R, Hase T et al. Administration of the selective cyclooxygenase (COX)-2 inhibitor etodolac prolongs cardiac allograft survival in a mouse model. Mol Med Report. 2010 Sep-Oct;3(5):771-4.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  41340-25-4